13S112: Molecular Mechanisms of Novel Therapeutic Agents in Vasculitis

Sunday, November 13, 2022

8:00 AM – 9:00 AM Eastern Time

Location: Terrace Ballroom IV

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Sharon Chung, MD

University of California, San Francisco
San Francisco, CA, United States

Disclosure(s): No financial relationships with ineligible companies to disclose

Several new therapeutics are in clinical trials for giant cell arteritis, including anti-GM-CSF receptor, mavrilimumab, and JAK-STAT inhibitors. New studies reveal the underlying molecular mechanisms by which these drugs are working to reduce vessel inflammation.

Data showing that T cells are critical for maintaining vessel inflammation and will highlight the role of T cell inhibition by these therapeutics in giant cell arteritis. New therapeutics for IgG4 vasculitis will also be discussed.

Learning Objectives:

Define the anti-inflammatory molecular mechanisms of anti-GM-CSF receptor in giant cell arteritis
Review the new findings of a tissue resident T cell population driving smoldering large vessel vasculitis amendable to JAK-STAT inhibition
Discuss the molecular mechanism of several therapeutic agents in IgG4 clinical trials

Presentations:

8:00 AM – 8:15 AM Eastern Time

GM-CSF Receptor Blockade Decreases Vascular Inflammation in Giant Cell Arteritis
Speaker: Maria Cid, MD – Hospital Clinic Barcelona
8:15 AM – 8:20 AM Eastern Time

Q&A
8:20 AM – 8:35 AM Eastern Time

JAK-STAT Signaling Inhibition Suppresses T-Cell Invasion in a Mouse Model of Giant Cell Arteritis
Speaker: Cornelia M. Weyand, MD, PhD – Mayo Clinic School of Medicine and Stanford University
8:35 AM – 8:40 AM Eastern Time

Q&A
8:40 AM – 8:55 AM Eastern Time

Understanding of IgG4-related Disease Transforming Therapeutic Targets
Speaker: John H. Stone, MD, MPH – Massachusetts General Hospital Rheumatology Unit, Harvard Medical School
8:55 AM – 9:00 AM Eastern Time

Q&A